Preclinical
Ben Zeskind, chief executive officer of Immuneering, spoke with BioSpace following the annual J.P. Morgan Healthcare conference in San Francisco.
What’s New at the J.P. Morgan Life Healthcare Conference?
With a new year underway, the U.S. Food and Drug Administration is doing some house-cleaning of sorts.
MR Solutions is continuing to expand its support network as its base of preclinical liquid helium free multimodality MRI systems become the norm in research laboratories across the world.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
TARA Biosystems, Inc. reported in vivo and in vitro functional data from a study of investigational candidate, MYK-491, showing that TARA’s human iPSC-derived organ-on-a-chip technology can directly measure in vivo cardiac performance.
MorphoSys AG announced presentation of so far unpublished data on tafasitamab, its proprietary key asset and investigational hemato-oncological drug candidate, at the upcoming 61th American Society of Hematology 2019 Annual Meeting, taking place from December 7-10, 2019 in Orlando, Florida.
Presentation at SITC Shows Potential to Flag Solid Tumours as a Target for the Immune System to Attack Using the Company’s DCOne® Cell Vaccine Loaded with a Foreign Antigen
Environmental impact is becoming a significant factor in the selection of suppliers even in preclinical imaging.
Preclinical results support the therapeutic potential of KB-1801 for the prevention of Cardiac Surgery-Associated Acute Kidney Injury and advancement into clinical development
PRESS RELEASES